CN102824380A - Application of Lianzhi anti-inflammation dropping pills in preparing medicine for suppressing HT1080 cell proliferation - Google Patents
Application of Lianzhi anti-inflammation dropping pills in preparing medicine for suppressing HT1080 cell proliferation Download PDFInfo
- Publication number
- CN102824380A CN102824380A CN2012103455616A CN201210345561A CN102824380A CN 102824380 A CN102824380 A CN 102824380A CN 2012103455616 A CN2012103455616 A CN 2012103455616A CN 201210345561 A CN201210345561 A CN 201210345561A CN 102824380 A CN102824380 A CN 102824380A
- Authority
- CN
- China
- Prior art keywords
- pills
- cell proliferation
- dropping pills
- lianzhi
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006187 pill Substances 0.000 title claims abstract description 22
- 230000004663 cell proliferation Effects 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 206010061218 Inflammation Diseases 0.000 title abstract 3
- 240000002853 Nelumbo nucifera Species 0.000 claims description 14
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 14
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 14
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 14
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 5
- 244000000231 Sesamum indicum Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 abstract description 3
- 239000003053 toxin Substances 0.000 abstract description 3
- 241000746375 Andrographis Species 0.000 abstract description 2
- 206010011224 Cough Diseases 0.000 abstract description 2
- 208000005647 Mumps Diseases 0.000 abstract description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 abstract description 2
- 201000007100 Pharyngitis Diseases 0.000 abstract description 2
- 208000006673 asthma Diseases 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 208000010805 mumps infectious disease Diseases 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 241000933211 Helicteres jamaicensis Species 0.000 abstract 1
- 206010001093 acute tonsillitis Diseases 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 230000008961 swelling Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 17
- 241000207961 Sesamum Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000010165 autogamy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of Lianzhi anti-inflammation dropping pills in preparing a medicine for suppressing HT1080 cell proliferation. The prescription of Lianzhi anti-inflammation dropping pills is common andrographis herb dry extract and screwtree root extract with specifications of 30 pills/bag and 6 bags/box; the dropping pills are taken orally, 30 pills once and 3 times per day; the dropping pills can realize the effects of clearing heat, removing toxin, cooling blood and diminishing swelling, and are used for treating the cough and asthma, mumps, acute tonsillitis and throat impediment and sore throat caused by heat and fire toxin in the lung and stomach; and the dropping pills can suppress HT1080 cell proliferation according to the current discovery.
Description
Technical field
The present invention relates to a kind of new purposes of Chinese patent medicine, relate in particular to lotus sesame anti-inflammatory dripping pills and suppress the application in the HT1080 cell proliferation medicine in preparation.
Background technology
Fibrosarcoma shows as deeply at the hard fixed joint of single-shot limitation, and the surface is nervous, and light is rubescent, is difficult for ulceration, and surface skin is normal usually, can move, but then fixing can not moving when invading adjacent tissue can be soaked into to subcutaneous fat, muscle, fascia etc.When originating from corium or invading corium afterwards like pathological changes, then atrophy, pigmentation and ulceration can take place in surface skin, show as gill fungus appearance lump once in a while, near local excision's cicatrix, multiple infringement can occur.After excising repeatedly, still common recurrence.After the recurrence systemic symptom can appear repeatedly.MET is found in lung, and occasionally in liver, metastases in local lymph node is then rarely found.More pernicious person's tumor is bigger, and soft, makes progress more rapid.Tumor also is found in the baby, even birth has the time.Present treatment means effect is all not so good.Lotus sesame anti-inflammatory dripping pills is the exclusive product of Hainan Yi Shun pharmaceutcal corporation, Ltd, does not also have it to suppress the bibliographical information of fibrosarcoma (HT1080) cell proliferation at present.
Summary of the invention
Goal of the invention: the object of the present invention is to provide lotus sesame anti-inflammatory dripping pills to suppress the application in the HT1080 cell proliferation medicine in preparation.
Technical scheme: lotus sesame anti-inflammatory dripping pills suppresses the application in the HT1080 cell proliferation medicine in preparation.
Lotus sesame anti-inflammatory dripping pills prescription is Herba Andrographis dry extractum (with total andrographolides juice), Radix Helicteris extractum, and specification is 30 ball/bags, 6 bags/box; Oral, one time 30 ball, 3 times on the one; The ability heat-clearing and toxic substances removing; The removing heat from blood detumescence, being used for the lung stomach has cough and asthma, mumps, tonsillitis, the sore throat pharyngalgia that Sheng causes in heat, the fire-toxin, finds that at present it can suppress the HT1080 cell proliferation.
Beneficial effect: lotus sesame anti-inflammatory dripping pills suppresses the HT1080 cell proliferation, and is respond well.
The specific embodiment
Lotus sesame anti-inflammatory dripping pills suppresses the experimentation data of HT1080 cell proliferation
1 experiment material
1.1 cell strain is used in experiment
Fibrosarcoma (HT1080), from our company's laboratory cell bank, DMEM+10% FBS is conventional to be cultivated.
1.2 experiment medicine
Research medicine: lotus sesame anti-inflammatory dripping pills, Hainan Yi Shun pharmaceutcal corporation, Ltd, lot number: 20110219
The medicinal liquid liquid storage: take by weighing 100mg lotus sesame anti-inflammatory dripping pills content, be dissolved in the 5ml dehydrated alcohol, 0.2 μ m filter filters, and 500 μ l doff manage packing ,-20 ℃ of storages, and 0.2 μ m filter filters the usefulness of dehydrated alcohol in order to matched group simultaneously.
1.3 experiment reagent
DMEM (the Cat.No.12100-061 Lot.No.758137 of GIBCO company); Hyclone (Hangzhoupro, sky, Zhejiang bio tech ltd Lot.No.100419); NaHCO3 (Shanghai hundred million chemical reagent company limited Cat.No.11810-033Lot.No.1088387 of a specified duration); Trypsin (AMRESCO company lot number: 2010/04); EDTA (AMRESCO company lot number: 2009/10); Penicillin G Sodium Salt (AMRESCO company lot number: 2010242); Streptomycin Sulfate (AMRESCO company lot number: 2010382); Dehydrated alcohol (Nanjing Chemistry Reagent Co., Ltd.'s lot number: 080310182); MTT (Biosharp lot number: 0793); PBS (laboratory autogamy);
1.4 experiment equipment
Lycra inverted microscope (German Leica model: DM1L); It is thus clear that-ultraviolet light microwell plate detector (U.S. MD company model: SPECTRA MAX 190); CO2 incubator (FORMA model: 3111); Super-clean bench (the safe and sound manufactured model of Su Jing group: SW-CJ-ZFD); Pure water appearance (U.S. Spring company model: S/N 020579); Accurate pipettor (French Gilson Inc model: P2); Electronic balance (German Sai Duolisi company limited model: BT323S); Full-automatic high-pressure autoclave (Japanese SANYO company model: MLS-3020); Desk-top electric drying oven with forced convection (the accurate experimental facilities in Shanghai company model: DHG9123A); Refrigerator (Siemens Company's model: KG18V21TI); Liquid nitrogen container (CBS model: 2001); Low speed centrifuge (Anting Scientific Instrument Factory, Shanghai's model: KA-1000); 0.2 μ m filter (MILLIPORE model: SLGP033RB); 10cm culture dish (NEST company), 96 well culture plates (NEST company); Cell counting count board; Centrifuge tube, pipet, Tips are some.
2 experimental techniques
1) the HT1080 cell carries out routine with DMEM+10% FBS in 37 ℃, 5% CO2 and cultivates (10cm culture dish), when cell grows to logarithmic (log) phase, and collecting cell; Discard culture fluid, PBS fine laundering 3 times adds 3ml 0.25% trypsin-0.04%EDTA; Behind 37 ℃ of digestion 2min,, behind the piping and druming cell it is changed in the centrifuge tube to wherein adding 5ml complete medium neutralization reaction; The centrifugal 5min of 1000rpm, adjustment concentration of cell suspension 3 * 10
4Individual/ml.
2) the cell kind is gone in 96 well culture plates, every hole adds cell suspension 180 μ l, culture plate put into cell culture incubator (37 ℃, 5% CO
2) the conventional cultivation.
3) according to the cell growing state, generally grow to 50%-70%, add lotus sesame anti-inflammatory dripping pills solution, continue to cultivate 24h.
4) add 20 μ l MTT solution (5mg/ml, i.e. 0.5%MTT) behind the 24h, continue to cultivate 4h.
5) the buckle method is removed supernatant behind the 4h, claps driedly gently with absorbent paper, and every hole adds 200 μ l dimethyl sulfoxide, puts low-speed oscillation 10min on the shaking table, and crystal is fully dissolved.Measure the extinction OD value in each hole at enzyme-linked immunosorbent assay instrument 490nm place.
6) background (do not add cell, only add culture fluid) is set simultaneously, control wells (the medicine dissolution medium of cell, same concentrations, culture fluid, MTT, dimethyl sulfoxide), 6 multiple holes of every settings.
7) result representes with the value-added suppression ratio of medicine pair cell:
Cell increment suppression ratio (%)=(control wells OD value-dosing holes OD value)/control wells OD value * 100%.Experiment repetition 3 times.
3 statistical dispositions
Adopt correlation analysis and Student t check in Microsoft Excel 2003 softwares, data are represented with mean ± S.D..
4 experimental results
Mtt assay experiment back statistical result showed; Compare with matched group; When dosage reaches 5mg/ml; To HT1080 cell inhibitory effect variant (P < 0.05), dosage this difference when 10mg/>ml has significance (P < 0.01), and utmost point significant difference (P < 0.001) is arranged when dosage reaches 15-20mg/>ml.
Table 1 lotus sesame anti-inflammatory dripping pills is to HT1080 cell inhibitory effect influence research
Annotate: compare * P < 0.01 with matched group; * P < 0.001
5 experiment conclusion
Lotus sesame anti-inflammatory dripping pills can suppress the HT1080 cell proliferation, reduces the cell growing number of HT1080 cell, and this effect is dose dependent.
Claims (1)
1. lotus sesame anti-inflammatory dripping pills suppresses the application in the HT1080 cell proliferation medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103455616A CN102824380B (en) | 2012-09-18 | 2012-09-18 | Application of Lianzhi anti-inflammation dropping pills in preparing medicine for suppressing HT1080 cell proliferation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103455616A CN102824380B (en) | 2012-09-18 | 2012-09-18 | Application of Lianzhi anti-inflammation dropping pills in preparing medicine for suppressing HT1080 cell proliferation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102824380A true CN102824380A (en) | 2012-12-19 |
| CN102824380B CN102824380B (en) | 2013-11-06 |
Family
ID=47327826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012103455616A Expired - Fee Related CN102824380B (en) | 2012-09-18 | 2012-09-18 | Application of Lianzhi anti-inflammation dropping pills in preparing medicine for suppressing HT1080 cell proliferation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102824380B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660364A (en) * | 2005-01-31 | 2005-08-31 | 北京正大绿洲医药科技有限公司 | 'Lianzhi' anti inflammation drop pill in use for clearing away heat and toxic material and preparation method |
-
2012
- 2012-09-18 CN CN2012103455616A patent/CN102824380B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660364A (en) * | 2005-01-31 | 2005-08-31 | 北京正大绿洲医药科技有限公司 | 'Lianzhi' anti inflammation drop pill in use for clearing away heat and toxic material and preparation method |
Non-Patent Citations (3)
| Title |
|---|
| 周鑫磊 等: "穿心莲内酯抗炎及抗肿瘤作用的研究进展", 《食品与药品》 * |
| 杨泽云 等: "莲芝消炎胶囊主要药效学研究", 《中医药通报*实验研究》 * |
| 覃华 等: "穿心莲内酯对S180小鼠体内抗肿瘤作用的研究", 《科学技术与工程》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102824380B (en) | 2013-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103816368A (en) | Extraction method and application of ginseng-containing plant composition | |
| CN103860802B (en) | Preparation method and application of Jieguqili tablet | |
| CN102824380A (en) | Application of Lianzhi anti-inflammation dropping pills in preparing medicine for suppressing HT1080 cell proliferation | |
| CN103690756B (en) | A kind of application of Qingfeiyihuo Tablets and preparation method | |
| CN102824614A (en) | Application of Wujin tablets for preparing medicines for suppressing PC-3 cell proliferation | |
| CN103479749B (en) | Preparation method and application of Gegenqinlian tablet | |
| CN103494915B (en) | Preparation method and application of breast lump dissipating tablet | |
| CN102824406B (en) | The red capsule for freeing collateral vessels of dragon suppresses the application in MJ cell proliferation in preparation | |
| CN103690601A (en) | Application and preparation method of heart strengthening tablets | |
| CN103463581B (en) | The preparation method of a kind of cholagogic and lithagogue tablet and application | |
| CN102824515A (en) | Application of Reduqing pills in preparation of medicine for inhibiting A-204 cell proliferation | |
| CN102824375A (en) | Application of Wuling capsule in preparation of medicament for inhibiting proliferation of U251 cell | |
| CN105055587A (en) | Extraction method and application of plant composition containing ginkgo leaves | |
| CN105056105B (en) | A kind of preparation method and application of shenmei stomach nourishing granule | |
| CN105106570A (en) | Extraction method and application of garlic-containing plant combination | |
| CN103655865B (en) | A kind of application of white Pollen Typhae sheet and preparation method | |
| CN105147869A (en) | Extracting method and application of plant composition containing green tea | |
| CN103479812B (en) | A kind of preparation method of children clearing heat sheet and application | |
| CN102836261A (en) | Application of kidney-tonifying capsules in preparing medicament for inhibiting MDA-MB-157 cell proliferation | |
| CN103721071B (en) | A kind of preparation method of YULU Baofei bolus and application | |
| CN105079162A (en) | Extraction method and application of honeysuckle-containing herbal composition | |
| CN102836363A (en) | Application of Pifukang solution (traditional Chinese medicine solution) to preparation of drugs for inhibiting HT-29 cell proliferation | |
| CN102824517A (en) | Application of suoquan capsules in preparing medicines for suppressing OS-732 cell proliferation | |
| CN103623212B (en) | A kind of preparation method and application consolidating ball | |
| CN103638489B (en) | Preparation method and application of kidney-tonifying pills |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: XINXIANG COLLEGE OF MEDICAL SCIENCE Free format text: FORMER OWNER: NANJING ZHENGLIANG PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20131017 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Di Desheng Inventor after: Zhao Erqi Inventor after: Gui Lihui Inventor after: Xu Zhongjie Inventor after: Liu Wei Inventor after: Yuan Huifeng Inventor after: Gu Zheng Inventor after: Li Songji Inventor after: Hou Tiantian Inventor after: He Huanhuan Inventor before: The inventor has waived the right to be mentioned |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 211300 NANJING, JIANGSU PROVINCE TO: 453003 XINXIANG, HENAN PROVINCE Free format text: CORRECT: INVENTOR; FROM: REQUEST NOT TO RELEASE THE NAME TO: ZHAI DESHENG GUI LIHUI XU ZHONGJIE LIU WEI YUAN HUIFENG GU ZHENG LI SONGJI HOU TIANTIAN HE HUANHUAN ZHAO ERQI |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131017 Address after: No. 601 Xinxiang City, Henan province Jinsui road 453003 Patentee after: Xinxiang Medical College Address before: Gu Tan Road Economic Development Zone in Gaochun County of Nanjing City, Jiangsu province 211300 branch No. 3 Building Room 607 Patentee before: Nanjing Zhengliang Medical Technology Co.,Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: NANJING ZHENGLIANG PHARMACEUTICAL TECHNOLOGY CO., Free format text: FORMER OWNER: XINXIANG COLLEGE OF MEDICAL SCIENCE Effective date: 20131126 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 453003 XINXIANG, HENAN PROVINCE TO: 211300 NANJING, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131126 Address after: Gu Tan Road Economic Development Zone in Gaochun County of Nanjing City, Jiangsu province 211300 branch No. 3 Building Room 607 Patentee after: Nanjing Zhengliang Medical Technology Co.,Ltd. Address before: No. 601 Xinxiang City, Henan province Jinsui road 453003 Patentee before: Xinxiang Medical College |
|
| ASS | Succession or assignment of patent right |
Owner name: HAIMEN JIANGHAI CONSTRUCTION INVESTMENT CO., LTD. Free format text: FORMER OWNER: NANJING ZHENGLIANG PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20140627 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 211300 NANJING, JIANGSU PROVINCE TO: 226100 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140627 Address after: 226100, 999, Guangzhou Road, Haimen, Jiangsu, Nantong Patentee after: HAIMEN JIANGHAI CONSTRUCTION INVESTMENT CO., LTD. Address before: Gu Tan Road Economic Development Zone in Gaochun County of Nanjing City, Jiangsu province 211300 branch No. 3 Building Room 607 Patentee before: Nanjing Zhengliang Medical Technology Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131106 Termination date: 20170918 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |